Drug intelligence / Profile preview

ICP-B794

Development stage: Phase 1
Lead developer: InnoCare Pharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ICP-B794 is an antibody-drug conjugate (ADC) developed by InnoCare Pharma. It targets B7-H3 (CD276), a protein overexpressed in various solid tumors. Preclinical studies have demonstrated that ICP-B794 exhibits superior anti-tumor activity and significant tumor-killing effects compared to other ADCs in animal models. The drug is designed to deliver a cytotoxic payload specifically to cancer cells expressing B7-H3, thereby minimizing off-target toxicity and maximizing therapeutic efficacy[1][2][4][5]. As of early 2025, the molecule has shown promising preclinical data but has not yet entered clinical trials.

Targets

B7-H3

Beyond the preview

Go deeper on ICP-B794.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICP-B794.

Explore the full profile